Healthcare // Analytics
News
8/13/2014
03:17 PM
Connect Directly
RSS
E-Mail
50%
50%

Intel, Michael J. Fox Foundation Take On Parkinson's Disease

Intel partners with the Michael J. Fox Foundation to explore how wearable devices could help advance Parkinson's disease research.

Wearable Tech: 5 Healthcare Wins
Wearable Tech: 5 Healthcare Wins
(Click image for larger view and slideshow.)

Intel and the Michael J. Fox Foundation for Parkinson's Research (MJFF) have partnered to help researchers and healthcare professionals improve patient care and explore new treatments for Parkinson's Disease through big data analytics.

The medical community's approach to Parkinson's disease has changed little since Dr. James Parkinson first described the condition in 1817, Todd Sherer, CEO of MJFF, said in a webcast news conference. "We are limited now by our ability to track the disease in an objective way and we rely on subjective measurements," he noted. "Assessment tools have not advanced dramatically since [1817]."

Intel and MJFF aim to change that, said Diane Bryant, senior VP and general manager of Intel's Data Center Group, through a jointly developed open solution that includes wearable devices, smartphones, and Cloudera CDH Hadoop-based big data analytic.

[For more on the potential of wearable devices in healthcare, see Wearable Tech Can Extend Clinical Analytics.]

Patients who suffer from the neurological disease, which affects about 5 million people worldwide, face symptoms such as tremors, sleep disruption, unsteady gait, and rigidity. In its first test of the new solution, 25 individuals -- 16 patients and nine control volunteers -- wore smartwatches to collect data on symptoms over four days and two clinic visits. Data was shared with search partners at Mount Sinai Hospital and Tel Aviv Medical Center in Israel.

All information is anonymized and secured in transmission and analysis, Bryant said. Going forward, patients' smartphones could transmit this information to the Hadoop solution for analysis. All information is anonymized and secured in transmission and analysis, Bryant added, and because it's an open system, other pilots or full-scale rollouts could use a variety of wearable devices from multiple vendors.

Currently, many physicians ask Parkinson's patients to keep daily logs with pen and paper, a time-consuming and error-prone task that individuals often fail to complete. Data scientists now are correlating digital data and manually collected patient information to develop algorithms to measure symptoms, according to Intel.

"I know that many doctors tell their patients to keep a log to track their Parkinson's," said Bret Parker, 46, who lives with Parkinson's. "I am not a compliant patient on that front. I pay attention to my Parkinson's, but it's not everything I am all the time. The wearables did that monitoring for me in a way I didn't even notice, and the study allowed me to take an active role in the process for developing a cure."

Wearable devices can capture more than 300 observations per minute, per patient. Intel's big data platform, housed in an Amazon Web Services cloud, uses an analytics application Intel developed to process and find changes in real-time. This allows researchers to objectively measure the disease's progress and eventually determine how various treatments help patients.

Soon, Bryant noted, the platform also could incorporate patient genome and clinical trial data, along with machine learning and graph analytics, to further support researchers' work.

This work could also help patients suffering from other conditions, Sherer pointed out, because Parkinson's disease includes symptoms seen across different illnesses or patient groups. In addition, the platform could be replicated to address the big data and analytics needs of researchers in other healthcare fields or even beyond the medical market, Bryant added.

Intel's involvement in Parkinson's research developed when Andy Grove, the company's third employee and a foundation board member who suffers from the condition, brought the idea to Bryant's team. Intel data scientists met with MJFF members, researchers, and patients to better understand the challenges faced by those with Parkinson's disease.

Relatively few Parkinson's patients participate in clinical trials, which are expensive, Bryant said, and researchers limit their sharing. To spur more research initiatives, MJFF has previously shared de-identified patient data and bio-samples with qualified researchers. Through its partnership with Intel, Sherer said, the foundation hopes to attract the attention of many more researchers through crowdsharing.

In its ninth year, Interop New York (Sept. 29 to Oct. 3) is the premier event for the Northeast IT market. Strongly represented vertical industries include financial services, government, and education. Join more than 5,000 attendees to learn about IT leadership, cloud, collaboration, infrastructure, mobility, risk management and security, and SDN, as well as explore 125 exhibitors' offerings. Register with Discount Code MPIWK to save $200 off Total Access & Conference Passes.

Alison Diana has written about technology and business for more than 20 years. She was editor, contributors, at Internet Evolution; editor-in-chief of 21st Century IT; and managing editor, sections, at CRN. She has also written for eWeek, Baseline Magazine, Redmond Channel ... View Full Bio

Comment  | 
Print  | 
More Insights
Comments
Newest First  |  Oldest First  |  Threaded View
Whoopty
50%
50%
Whoopty,
User Rank: Ninja
8/14/2014 | 11:23:07 AM
Wearables
As impressive as wearables have become for consumers, it's their application for health reasons that I think we're going to see the most development in the next few years. They're really a pre-cursor to nanobot injections, so it's exciting seeing the first wave of these begin to become available. 

As long as the data is truly anomymised and is opt-in, I'm all for it. It's important that this sort of highly personal data doesn't become fodder for insurance industries. 
Alison_Diana
50%
50%
Alison_Diana,
User Rank: Author
8/14/2014 | 9:46:00 AM
Exciting Times
Big data, wearables, and analytics are fueling so much hope in medicine these days. As I wrote earlier this month, Philips and Accenture are targeting ALS (also known as Lou Gehrig's disease), while Mount Sinai Hospital and Saffron Technology want to improve cardiac care. While all these projects initially focus on one specific condition, future pilots (and full-fledged programs) could relatively easily expand into other diseases or afflictions. In addition, many could be used to help elderly people who want to live at home, granting them more autonomy whle simultaneously reducing financial and staffing pressures.
Big Love for Big Data? The Remedy for Healthcare Quality Improvements
Big Love for Big Data? The Remedy for Healthcare Quality Improvements
Healthcare data is nothing new, but yet, why do healthcare improvements from quantifiable data seem almost rare today? Healthcare administrators have a wealth of data accessible to them but aren't sure how much of that data is usable or even correct.
Register for InformationWeek Newsletters
White Papers
Current Issue
InformationWeek Must Reads Oct. 21, 2014
InformationWeek's new Must Reads is a compendium of our best recent coverage of digital strategy. Learn why you should learn to embrace DevOps, how to avoid roadblocks for digital projects, what the five steps to API management are, and more.
Video
Slideshows
Twitter Feed
InformationWeek Radio
Archived InformationWeek Radio
A roundup of the top stories and trends on InformationWeek.com
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.